Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer

Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer

Source: 
Fierce Pharma
snippet: 

In less than 24 hours, the FDA handed out one rejection and one thumbs-up to two rival drugs for a rare stomach cancer.

On the heels of turning down Blueprint Medicines’ Ayvakit as a therapy for heavily pretreated patients with gastrointestinal stromal tumors (GIST), the FDA has green lit Deciphera Phamaceuticals’ Qinlock (ripretinib) as the first drug specifically approved in that same setting.